Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 in Gastrointestinal Cancers
NCT06428409Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), sponsored by Merck & Co.. Started Jun 2024; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06428409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428409.